The effects of aripiprazole on electrocardiography in children with pervasive developmental disorders

Jason G. Ho, Randall L. Caldwell, Christopher J. McDougle, Danielle K. Orsagh-Yentis, Craig A. Erickson, David J. Posey, Kimberly A. Stigler

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objectives: Psychotropic medications, including the atypical antipsychotics, have historically been scrutinized for cardiac effects and risk of sudden death. Aripiprazole is an atypical antipsychotic approved for pediatric use in schizophrenia, bipolar I disorder, and autistic disorder. Adult studies have evaluated aripiprazole's effects on electrocardiograms, but no pediatric studies have been published to date. Methods: Electrocardiographic data were collected from children and adolescents participating in a 14-week, prospective, open-label study (n=25) of aripiprazole for irritability in pervasive developmental disorder not otherwise specified and Asperger's disorder. A 12-lead electrocardiogram was obtained at the baseline and end point visits. The electrocardiograms were evaluated for abnormal findings, and the PR, QRS, QTc, and RR intervals were recorded. The QT interval was corrected using Bazett's, United States Food and Drug Administration (FDA) Pharmacology Division, and Fridericia's formulas. Results: Twenty-four subjects received both baseline and posttreatment electrocardiograms. The mean age was 8.6 years (range 5-17 years). The average final aripiprazole dose was 7.8mg/day (range 2.5-15mg/day). There were no significant differences noted with the PR, QRS, RR, and QTc intervals after aripiprazole therapy. Also, there was no significant correlation between the dose given and the percent change in the QTc. No post-treatment QTc exceeded 440ms. Conclusions: To our knowledge, this is the first systematic evaluation of the cardiac effects of aripiprazole in children and adolescents. The results are consistent with previously published literature in adults that aripiprazole has no significant cardiac effects and can be deemed a low risk for causing sudden death. It will be important to confirm these findings in a randomized controlled trial.

Original languageEnglish
Pages (from-to)277-283
Number of pages7
JournalJournal of Child and Adolescent Psychopharmacology
Volume22
Issue number4
DOIs
StatePublished - Aug 1 2012

Fingerprint

Electrocardiography
Sudden Death
Antipsychotic Agents
Pediatrics
Asperger Syndrome
United States Food and Drug Administration
Autistic Disorder
Aripiprazole
Bipolar Disorder
Schizophrenia
Randomized Controlled Trials
Pharmacology
Therapeutics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pediatrics, Perinatology, and Child Health
  • Psychiatry and Mental health

Cite this

Ho, J. G., Caldwell, R. L., McDougle, C. J., Orsagh-Yentis, D. K., Erickson, C. A., Posey, D. J., & Stigler, K. A. (2012). The effects of aripiprazole on electrocardiography in children with pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology, 22(4), 277-283. https://doi.org/10.1089/cap.2011.0129

The effects of aripiprazole on electrocardiography in children with pervasive developmental disorders. / Ho, Jason G.; Caldwell, Randall L.; McDougle, Christopher J.; Orsagh-Yentis, Danielle K.; Erickson, Craig A.; Posey, David J.; Stigler, Kimberly A.

In: Journal of Child and Adolescent Psychopharmacology, Vol. 22, No. 4, 01.08.2012, p. 277-283.

Research output: Contribution to journalArticle

Ho, JG, Caldwell, RL, McDougle, CJ, Orsagh-Yentis, DK, Erickson, CA, Posey, DJ & Stigler, KA 2012, 'The effects of aripiprazole on electrocardiography in children with pervasive developmental disorders', Journal of Child and Adolescent Psychopharmacology, vol. 22, no. 4, pp. 277-283. https://doi.org/10.1089/cap.2011.0129
Ho, Jason G. ; Caldwell, Randall L. ; McDougle, Christopher J. ; Orsagh-Yentis, Danielle K. ; Erickson, Craig A. ; Posey, David J. ; Stigler, Kimberly A. / The effects of aripiprazole on electrocardiography in children with pervasive developmental disorders. In: Journal of Child and Adolescent Psychopharmacology. 2012 ; Vol. 22, No. 4. pp. 277-283.
@article{d6014cbce12e4f9b8d3fbf9e4aac7c92,
title = "The effects of aripiprazole on electrocardiography in children with pervasive developmental disorders",
abstract = "Objectives: Psychotropic medications, including the atypical antipsychotics, have historically been scrutinized for cardiac effects and risk of sudden death. Aripiprazole is an atypical antipsychotic approved for pediatric use in schizophrenia, bipolar I disorder, and autistic disorder. Adult studies have evaluated aripiprazole's effects on electrocardiograms, but no pediatric studies have been published to date. Methods: Electrocardiographic data were collected from children and adolescents participating in a 14-week, prospective, open-label study (n=25) of aripiprazole for irritability in pervasive developmental disorder not otherwise specified and Asperger's disorder. A 12-lead electrocardiogram was obtained at the baseline and end point visits. The electrocardiograms were evaluated for abnormal findings, and the PR, QRS, QTc, and RR intervals were recorded. The QT interval was corrected using Bazett's, United States Food and Drug Administration (FDA) Pharmacology Division, and Fridericia's formulas. Results: Twenty-four subjects received both baseline and posttreatment electrocardiograms. The mean age was 8.6 years (range 5-17 years). The average final aripiprazole dose was 7.8mg/day (range 2.5-15mg/day). There were no significant differences noted with the PR, QRS, RR, and QTc intervals after aripiprazole therapy. Also, there was no significant correlation between the dose given and the percent change in the QTc. No post-treatment QTc exceeded 440ms. Conclusions: To our knowledge, this is the first systematic evaluation of the cardiac effects of aripiprazole in children and adolescents. The results are consistent with previously published literature in adults that aripiprazole has no significant cardiac effects and can be deemed a low risk for causing sudden death. It will be important to confirm these findings in a randomized controlled trial.",
author = "Ho, {Jason G.} and Caldwell, {Randall L.} and McDougle, {Christopher J.} and Orsagh-Yentis, {Danielle K.} and Erickson, {Craig A.} and Posey, {David J.} and Stigler, {Kimberly A.}",
year = "2012",
month = "8",
day = "1",
doi = "10.1089/cap.2011.0129",
language = "English",
volume = "22",
pages = "277--283",
journal = "Journal of Child and Adolescent Psychopharmacology",
issn = "1044-5463",
publisher = "Mary Ann Liebert Inc.",
number = "4",

}

TY - JOUR

T1 - The effects of aripiprazole on electrocardiography in children with pervasive developmental disorders

AU - Ho, Jason G.

AU - Caldwell, Randall L.

AU - McDougle, Christopher J.

AU - Orsagh-Yentis, Danielle K.

AU - Erickson, Craig A.

AU - Posey, David J.

AU - Stigler, Kimberly A.

PY - 2012/8/1

Y1 - 2012/8/1

N2 - Objectives: Psychotropic medications, including the atypical antipsychotics, have historically been scrutinized for cardiac effects and risk of sudden death. Aripiprazole is an atypical antipsychotic approved for pediatric use in schizophrenia, bipolar I disorder, and autistic disorder. Adult studies have evaluated aripiprazole's effects on electrocardiograms, but no pediatric studies have been published to date. Methods: Electrocardiographic data were collected from children and adolescents participating in a 14-week, prospective, open-label study (n=25) of aripiprazole for irritability in pervasive developmental disorder not otherwise specified and Asperger's disorder. A 12-lead electrocardiogram was obtained at the baseline and end point visits. The electrocardiograms were evaluated for abnormal findings, and the PR, QRS, QTc, and RR intervals were recorded. The QT interval was corrected using Bazett's, United States Food and Drug Administration (FDA) Pharmacology Division, and Fridericia's formulas. Results: Twenty-four subjects received both baseline and posttreatment electrocardiograms. The mean age was 8.6 years (range 5-17 years). The average final aripiprazole dose was 7.8mg/day (range 2.5-15mg/day). There were no significant differences noted with the PR, QRS, RR, and QTc intervals after aripiprazole therapy. Also, there was no significant correlation between the dose given and the percent change in the QTc. No post-treatment QTc exceeded 440ms. Conclusions: To our knowledge, this is the first systematic evaluation of the cardiac effects of aripiprazole in children and adolescents. The results are consistent with previously published literature in adults that aripiprazole has no significant cardiac effects and can be deemed a low risk for causing sudden death. It will be important to confirm these findings in a randomized controlled trial.

AB - Objectives: Psychotropic medications, including the atypical antipsychotics, have historically been scrutinized for cardiac effects and risk of sudden death. Aripiprazole is an atypical antipsychotic approved for pediatric use in schizophrenia, bipolar I disorder, and autistic disorder. Adult studies have evaluated aripiprazole's effects on electrocardiograms, but no pediatric studies have been published to date. Methods: Electrocardiographic data were collected from children and adolescents participating in a 14-week, prospective, open-label study (n=25) of aripiprazole for irritability in pervasive developmental disorder not otherwise specified and Asperger's disorder. A 12-lead electrocardiogram was obtained at the baseline and end point visits. The electrocardiograms were evaluated for abnormal findings, and the PR, QRS, QTc, and RR intervals were recorded. The QT interval was corrected using Bazett's, United States Food and Drug Administration (FDA) Pharmacology Division, and Fridericia's formulas. Results: Twenty-four subjects received both baseline and posttreatment electrocardiograms. The mean age was 8.6 years (range 5-17 years). The average final aripiprazole dose was 7.8mg/day (range 2.5-15mg/day). There were no significant differences noted with the PR, QRS, RR, and QTc intervals after aripiprazole therapy. Also, there was no significant correlation between the dose given and the percent change in the QTc. No post-treatment QTc exceeded 440ms. Conclusions: To our knowledge, this is the first systematic evaluation of the cardiac effects of aripiprazole in children and adolescents. The results are consistent with previously published literature in adults that aripiprazole has no significant cardiac effects and can be deemed a low risk for causing sudden death. It will be important to confirm these findings in a randomized controlled trial.

UR - http://www.scopus.com/inward/record.url?scp=84865325369&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865325369&partnerID=8YFLogxK

U2 - 10.1089/cap.2011.0129

DO - 10.1089/cap.2011.0129

M3 - Article

VL - 22

SP - 277

EP - 283

JO - Journal of Child and Adolescent Psychopharmacology

JF - Journal of Child and Adolescent Psychopharmacology

SN - 1044-5463

IS - 4

ER -